Milan/Lucca, 29 April 2022– The Annual General Meeting of Shareholders of Kedrion S.p.A. has approved today the individual financial statements of the Company for the year ended 31 December 2021.
READ THE CONSOLIDATED FINANCIAL STATEMENTS 2021
Kedrion Biopharma
Kedrion is a biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders. The company operates through a fully integrated business model from the collection of plasma in its own centers in the United States to fractionation and production in its manufacturing facilities located in Italy, Hungary and North America. Headquartered in Castelvecchio Pascoli (Lucca, Italy), Kedrion has over 2,800 employees and a commercial presence in 100 countries worldwide.
